VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations·BOSTON, MA·FY end 12/31·CIK 875320

CEO Pay Ratio

80:1

Reshma Kewalramani

CEO Total Comp

$21.1M

Reshma Kewalramani

Median Employee

$264,487

Revenue

$12.0B

FY 2025

Net Income

$4.0B

FY 2025

Free Cash Flow

$3.2B

FY 2025

Net Margin

32.9%

Insider Net (180d)

-$28.2M

0 buys / 25 sales

CEO Pay Accountability

CEO comp as % of net income

0.53%

For every $1,000 of profit, $5.35 flows to the CEO.

CEO comp as % of buybacks

1.05%

CEO comp equals 10.5‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$12.0B	$11.0B	$9.9B	$8.9B	$7.6B
Gross Profit	—	—	—	—	—	—
Operating Income	$4.2B	-$232.9M	$3.8B	$4.3B	$2.8B
Net Income	$4.0B	-$535.6M	$3.6B	$3.3B	$2.3B
Operating CF	$3.6B	-$492.6M	$3.5B	$4.1B	$2.6B
Capex	$437.6M	$297.7M	$200.4M	$204.7M	$235.0M
Free Cash Flow	$3.2B	-$790.3M	$3.3B	$3.9B	$2.4B
Buybacks	$2.0B	$1.2B	$427.6M	$0	$1.4B
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	34.8%	-2.1%	38.8%	48.2%	36.7%
Net Margin	32.9%	-4.9%	36.7%	37.2%	30.9%
FCF Margin	26.6%	-7.2%	33.8%	44.0%	31.8%
R&D / Revenue	—	—	—	—	40.3%	—
Effective Tax	14.9%	315.5%	17.4%	21.5%	14.2%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	63.2%	-148.9%	12.8%	0.0%	59.2%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Reshma KewalramaniCEO and President	$1.6M	$15.0M	—	$4.1M	$423.4K	$21.1M
Stuart A. ArbuckleFormer EVP & Chief Operating Officer	$521.5K	$9.3M	—	—	$132.9K	$10.0M
Charles F. WagnerJr.	$974.8K	$5.3M	—	$2.0M	$51.2K	$8.2M
Nia TatsisEVP & Chief Regulatory and Quality Officer	$750.0K	$4.9M	—	$1.3M	$42.2K	$7.0M
Amit Sachdev	$700.0K	$4.9M	—	$1.2M	$21.3K	$6.8M
Carmen Bozic	$835.0K	$4.4M	—	$1.4M	$57.5K	$6.6M